1. Home
  2. QLGN vs SLE Comparison

QLGN vs SLE Comparison

Compare QLGN & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • SLE
  • Stock Information
  • Founded
  • QLGN 1996
  • SLE 2014
  • Country
  • QLGN United States
  • SLE United States
  • Employees
  • QLGN N/A
  • SLE N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • SLE Services-Misc. Amusement & Recreation
  • Sector
  • QLGN Health Care
  • SLE Consumer Discretionary
  • Exchange
  • QLGN Nasdaq
  • SLE Nasdaq
  • Market Cap
  • QLGN 3.1M
  • SLE 3.6M
  • IPO Year
  • QLGN N/A
  • SLE 2019
  • Fundamental
  • Price
  • QLGN $1.90
  • SLE $3.20
  • Analyst Decision
  • QLGN
  • SLE Strong Buy
  • Analyst Count
  • QLGN 0
  • SLE 2
  • Target Price
  • QLGN N/A
  • SLE $100.00
  • AVG Volume (30 Days)
  • QLGN 125.5K
  • SLE 121.3K
  • Earning Date
  • QLGN 08-26-2025
  • SLE 08-14-2025
  • Dividend Yield
  • QLGN N/A
  • SLE N/A
  • EPS Growth
  • QLGN N/A
  • SLE N/A
  • EPS
  • QLGN N/A
  • SLE N/A
  • Revenue
  • QLGN N/A
  • SLE $13,576,000.00
  • Revenue This Year
  • QLGN N/A
  • SLE N/A
  • Revenue Next Year
  • QLGN N/A
  • SLE $30.36
  • P/E Ratio
  • QLGN N/A
  • SLE N/A
  • Revenue Growth
  • QLGN N/A
  • SLE N/A
  • 52 Week Low
  • QLGN $1.61
  • SLE $3.07
  • 52 Week High
  • QLGN $11.50
  • SLE $53.20
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 32.76
  • SLE 32.82
  • Support Level
  • QLGN $1.61
  • SLE $3.98
  • Resistance Level
  • QLGN $1.91
  • SLE $4.26
  • Average True Range (ATR)
  • QLGN 0.16
  • SLE 0.47
  • MACD
  • QLGN -0.01
  • SLE -0.05
  • Stochastic Oscillator
  • QLGN 26.48
  • SLE 6.10

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.

About SLE Super League Enterprise Inc.

Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.

Share on Social Networks: